|Conţinutul numărului revistei|
|Ultima descărcare din IBN:|
|Căutarea după subiecte |
similare conform CZU
|Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (633)|
| SM ISO690:2012|
MUSTEAŢĂ, Vasile; CORCIMARU, Ion; MEREUŢĂ, Ion; MUSTEAŢĂ, Larisa; ROBU, Maria. Caracteristicile epidemiologice şi realizările manageriale actuale în leucemia mieloidă cronică. In: Revista ştiinţifico-practică "Info-Med" . 2016, nr. 2(28-2), pp. 82-90. ISSN 1810-3936.
|Revista ştiinţifico-practică "Info-Med"|
|Numărul 2(28-2) / 2016 / ISSN 1810-3936|
The current study comprized 125 patients with chronic myeloid leukemia (CML), who had been followed up and treated at the Institute of Oncology in 2004 – 2014. The diagnosis was established in the late chronic phase in 113 (90.4%) cases, in the accelerated and acute phases in 12 (9.6%) cases. The patient age ranged from 19 to 81 years (median age – 46.1 ± 2.13 years old), that indicated the predominant affection of the workable population. The majority of patients (66.7 ± 5.14%) proved to be heavily exposed to insolation within the framework of professional activities and daily life that might be considered the favoring factor of the development of CML. The severity of the disease and the limited life expectation were proved by the relatively low values of the overall survival: 3- and 5-year survival were accounted at 57.5% and 36.5%, respectively. The treatment of CML in the chronic phase and accelerated phase without complications may be realized in the outpatient department or in a daily hospital ward. The treatment of CML in the accelerated phase with complications (bleeding, thrombotic, infections) and in the acute phase should be realized in the specialized departments of hematology. The drug imatinib mesylate and nilotinib constitute the first-line therapeutic option in the chronic phase and in the accelerated phase, being superior to the conventional chemotherapy and α-interferon due to the possibility of achievement of a fast complete hematologic response, complete cytogenetic response and due to the considerable increase of a life quality and longevity of patients. In the GIPAP affiliated investigational group the one-year, 2- and 3-year survival rates constituted 97%, 78% şi 66%, respectively, and turned to be superior (p<0,05) to those in the investigational group without imatinib mesylate treatment (3-year survival – 44.5%). The median longevity (61.65 ± 4.81 years) proved to be much higher (p<0.05) in the age group of 40 – 49 years. The masculine gender, age groups of 20 – 29, 60 – 69, over 70 years and the ECOG-WHO score of 2 – 3 points after the induction chemotherapy may be considered as unfavorable prognostic factors.
chronic myeloid leukemia, favoring factor of the development, complete hematologic response, overall survival, unfavorable prognostic factors